Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenerative Medical Technology (RMTG) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$0.35.

  • Regenerative Medical Technology's EPS (Basic) fell 40000.0% to -$0.35 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.56, marking a year-over-year decrease of 3333.33%. This contributed to the annual value of -$0.44 for FY2024, which is 2336.46% up from last year.
  • Latest data reveals that Regenerative Medical Technology reported EPS (Basic) of -$0.35 as of Q3 2025, which was down 40000.0% from -$0.1 recorded in Q2 2025.
  • Over the past 5 years, Regenerative Medical Technology's EPS (Basic) peaked at $0.01 during Q4 2022, and registered a low of -$0.82 during Q3 2021.
  • For the 5-year period, Regenerative Medical Technology's EPS (Basic) averaged around -$0.17, with its median value being -$0.13 (2023).
  • As far as peak fluctuations go, Regenerative Medical Technology's EPS (Basic) soared by 10413.28% in 2022, and later plummeted by 262816.19% in 2023.
  • Over the past 5 years, Regenerative Medical Technology's EPS (Basic) (Quarter) stood at -$0.14 in 2021, then surged by 104.13% to $0.01 in 2022, then tumbled by 2628.16% to -$0.14 in 2023, then soared by 64.1% to -$0.05 in 2024, then tumbled by 586.32% to -$0.35 in 2025.
  • Its EPS (Basic) stands at -$0.35 for Q3 2025, versus -$0.1 for Q2 2025 and -$0.06 for Q1 2025.